AstraZeneca CEO says AI is reshaping drug development AstraZeneca CEO Pascal Soriot highlighted artificial intelligence’s role in improving productivity within the drug development industry. AI assists in designing medicines faster and smarter, from identifying new targets to optimizing molecular design and predicting potential side effects. The company leverages AI models, through partnerships like the one with Tempus AI, to analyze data and enhance decision-making, significantly increasing the probability of success in late-stage clinical trials.

• AI improves productivity in drug development by enabling faster and smarter medicine design.
• Practical applications of AI are evident across drug discovery and development stages.
• AI helps in identifying new drug targets and optimizing molecular design.
• AI aids in predicting potential side effects of drug molecules.
• Partnerships with AI companies like Tempus AI help analyze data for better decision-making.
• AI models are used to analyze clinical and laboratory data to predict the success probability of Phase 3 trials.
• Increasing the probability of success in trials leads to enormous productivity improvements, especially given the high costs of drug development.